Caxton Associates (New York)’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Caxton Associates (New York)’s Portfolio CDMO Stock Details CDMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-19,166	Closed	-$492K	–	625
2021 Q2	$492K	Sell	19,166 -4,090	-18%	-$87.4K	0.05%	177
2021 Q1	$424K	Buy	+23,256	New	+$386K	0.04%	192
2020 Q3	–	Sell	-27,784	Closed	-$182K	–	541
2020 Q2	$182K	Buy	+27,784	New	+$155K	0.02%	386
2020 Q1	–	Sell	-19,192	Closed	-$147K	–	627
2019 Q4	$147K	Buy	+19,192	New	+$112K	0.02%	374
2018 Q4	–	Sell	-27,960	Closed	-$192K	–	501
2018 Q3	$192K	Buy	+27,960	New	+$166K	0.01%	381

Other funds holding CDMO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Caxton Associates (New York)'s CDMO Position: Q3 2021 in Review

Caxton Associates (New York) sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q3 2021, closing a stake of 19,166 shares — an estimated $492K sold.

Caxton Associates (New York) first reported a position in CDMO in Q3 2018 and held it in 5 quarters. The position peaked at $492K in Q2 2021. 161 funds tracked by Wall St. Rank hold CDMO as of Q3 2021.

Caxton Associates (New York) reported no remaining Avid Bioservices, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Caxton Associates (New York) sold 19,166 Avid Bioservices, Inc. Common Stock shares in Q3 2021, an estimated $492K.
Caxton Associates (New York) first reported a position in Avid Bioservices, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
Caxton Associates (New York)'s Avid Bioservices, Inc. Common Stock position peaked at $492K in Q2 2021.
161 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q3 2021.

Based on Caxton Associates (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.